Silexion Therapeutics Ltd.
NASDAQ Global MarketTotal Valuation
Silexion Therapeutics Ltd. carries a market capitalization of 2.04M, placing it among publicly traded companies globally. Its enterprise value stands at 20.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.04M |
| Enterprise Value | 20.66M |
Share Statistics
Silexion Therapeutics Ltd. currently has 3.39M shares outstanding.
| Shares Outstanding | 3.39M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.36 |
| P/TBV Ratio | 72.47 |
| P/FCF Ratio | -1.76 |
| P/OCF Ratio | -1.76 |
Financial Position
Silexion Therapeutics Ltd. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 683.51, indicating elevated leverage, while an interest coverage ratio of -1,271.90 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.00 |
| Quick Ratio | 0.59 |
| Debt / Equity | 683.51 |
| Debt / EBITDA | -0.16 |
| Interest Coverage | -1,271.90 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -200.00 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 3,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Silexion Therapeutics Ltd.'s stock has declined approximately -96.58947% over the past 52 weeks. The 50-day moving average sits at 8.03, while the 200-day moving average is 25.35.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96.58947% |
| 50-Day Moving Average | 8.03 |
| 200-Day Moving Average | 25.35 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -12.72M, while operating income came in at -12.73M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -12.73M |
| Pretax Income | -12.91M |
| Net Income | -12.91M |
| EBITDA | -12.72M |
| EBIT | -12.73M |
| Earnings Per Share (EPS) | -7.84 |
Balance Sheet
Silexion Therapeutics Ltd. holds 2.41M in cash and equivalents against 1.99M in total debt, resulting in a net debt position of -860,000.00. Total book value stands at -57.85M, with working capital of 5,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 2.41M |
| Total Debt | 1.99M |
| Net Debt | -860,000.00 |
| Equity (Book Value) | -57.85M |
| Book Value Per Share | -35.12 |
| Working Capital | 5,000.00 |
Cash Flow
Silexion Therapeutics Ltd. produced -12.01M in operating cash flow over the past twelve months. After subtracting -3,000.00 in capital expenditures, free cash flow totaled -12.01M - equivalent to -7.29 per share.
| Operating Cash Flow | -12.01M |
| Capital Expenditures | -3,000.00 |
| Free Cash Flow | -12.01M |
| FCF Per Share | -7.29 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -39.32 |
| FCF Yield | -56.95 |
Stock Splits
Silexion Therapeutics Ltd.'s most recent stock split took place on May 29, 2026 with a 10:1 split ratio.
| Last Split Date | 5/29/2026 |
| Split Ratio | 10:1 |
Scores
Silexion Therapeutics Ltd. posts an Altman Z-Score of -23.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -23.81 |